[1] |
Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol, 2010, 16(4):418-424.
|
[2] |
Zhou XD, Tang ZY, Fan J, et al. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2009, 135(8):1073-1080.
|
[3] |
Zhou H, Wang H, Zhou D, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis[J]. Eur J Cancer, 2010, 46(6):1056-1061.
|
[4] |
Poultsides GA, Zhu AX, Choti MA, et al. Intrahepatic cholangiocarcinoma[J]. Surg Clin North Am, 2010, 90(4):817-837.
|
[5] |
Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC[J]. J Gastroenterol, 2010, 45(12):1272-1282.
|
[6] |
Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star[J]. Gastroenterology, 2009, 137(1):26-29.
|
[7] |
Shen WF, Zhong W, Xu F, et al. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma[J]. World J Gastroenterol, 2009, 15(47):5976-5982.
|
[8] |
Yamamoto M, Ariizumi S, Otsubo T, et al. Intrahepatic cholangiocarcinoma diagnosed preoperatively as hepatocellular carcinoma[J]. J Surg Oncol, 2004, 87(2):80-83, 83-84.
|
[9] |
Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma[J]. Hepatology, 2011, 54(1):173-184.
|
[10] |
Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? a meta-analysis of risk factors for intrahepatic cholangiocarcinoma[J]. J Hepatol, 2012, 57(1):69-76.
|
[11] |
Malaguarnera G, Paladina I, Giordano M, et al. Serum markers of intrahepatic cholangiocarcinoma[J]. Dis Markers, 2013, 34(4):219-228.
|
[12] |
Zhou YM, Yang JM, Li B, et al. Clinicopathologic characteristics of intrahepatic cholangiocarcinoma in patients with positive serum a-fetoprotein[J]. World J Gastroenterol, 2008, 14(14):2251-2254.
|
[13] |
Witjes CD, Polak WG, Verhoef C, et al. Increased alpha-fetoprotein serum level is predictive for survival and recurrence of hepatocellular carcinoma in non-cirrhotic livers[J]. Dig Surg, 2012, 29(6):522-528.
|
[14] |
Gadelhak NA, Gadelhak SA, El-Morsi DA, et al. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma[J]. Hepatogastroenterology, 2009, 56(94/95):1417-1424.
|
[15] |
de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment[J]. J Clin Oncol, 2011, 29(23):3140-3145.
|
[16] |
Guglielmi A, Ruzzenente A, Campagnaro T, et al. Patterns and prognostic significance of lymph node dissection for surgical treatment of perihilar and intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg, 2013, 17(11):1917-1928.
|
[17] |
Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival[J]. Ann Surg Oncol, 2009, 16(11):3048-3056.
|
[18] |
Li DY, Zhang HB, Yang N, et al. Routine lymph node dissection may be not suitable for all intrahepatic cholangiocarcinoma patients: results of a monocentric series[J]. World J Gastroenterol, 2013, 19(47):9084-9091.
|
[19] |
Morine Y, Shimada M, Utsunomiya T, et al. Clinical impact of lymph node dissection in surgery for peripheral-type intrahepatic cholangiocarcinoma[J]. Surg Today, 2012, 42(2):147-151.
|